BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18559410)

  • 1. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
    Case D; Morgan T
    Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
    [No Abstract]   [Full Text] [Related]  

  • 2. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivariate sequential designs for phase II trials.
    Conaway MR; Petroni GR
    Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 6. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: tumor growth, patient survival, and the search for the optimal phase II efficacy endpoint.
    Takimoto CH
    Oncologist; 2008 Oct; 13(10):1043-5. PubMed ID: 18832191
    [No Abstract]   [Full Text] [Related]  

  • 8. Alternate endpoints for screening phase II studies.
    Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
    Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 11. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
    Kovalchik S; Mietlowski W
    Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 14. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
    Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-PĂ©lissier S; Bonnetain F
    Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II studies and their ethics.
    Abratt RP; Reece WH; Enas NH; Stephens R
    J Clin Oncol; 2005 Dec; 23(36):9443. PubMed ID: 16361651
    [No Abstract]   [Full Text] [Related]  

  • 18. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
    Ratain MJ; Karrison TG
    Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
    [No Abstract]   [Full Text] [Related]  

  • 19. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.